drug companies

 
Motsoaledi: Big pharma's 'satanic' plot is genocide
Motsoaledi: Big pharma's 'satanic' plot is genocide
Health Minister Aaron Motsoaledi has accused a group of multinational...
Generic cancer drug - access not guaranteed
Generic cancer drug - access not guaranteed
Imatinib is used primarily for treatment of chronic myelogenous leukemia, or CML, and gastrointestinal stromal tumours, or GIST. The government of...
Patent exemption extended for world's poorest nations
Patent exemption extended for world's poorest nations
That's because, on June 11, the council in the World Trade Organisation (WTO) responsible for overseeing the agreement on Trade Related Aspects...
Zim drug companies under the weather
Zim drug companies under the weather
Zimbabwe's pharmaceutical manufacturers are seeking government intervention over what they say are unfair trade policies imposed by South...
Impoverished patients benefit from rejected drug patent
Impoverished patients benefit from rejected drug patent
On Monday, India's Supreme Court upheld decisions by lower courts to reject a patent on Gleevec, or Glivec, a cancer medicine produced by...
Cheap drugs a bitter pill for the West
Cheap drugs a bitter pill for the West
Would you rather pay $12 a dose for malaria drugs or $2.40 – and potentially boost your country's economy at the same time?
Exposed: Bitter pill of bad pharma
Exposed: Bitter pill of bad pharma
If you are shocked by accounts of politicians fiddling their expenses, try this one: in the United States, doctor and popular media personality Drew...
There's solace in numbers in the world of rare diseases
There's solace in numbers in the world of rare diseases
In the world of rare diseases, the story of the Daniels family in Kraaifontein, Cape Town, is probably typical.
Pfizer to buy Wyeth, will cut jobs
Pfizer to buy Wyeth, will cut jobs
Pfizer Inc is buying rival drug maker Wyeth in a $68-billion deal that will increase its revenue by 50 percent, solidify its No 1 rank in the...
Pfizer nears $68bn deal to buy Wyeth, say sources
Pfizer nears $68bn deal to buy Wyeth, say sources
Pfizer Inc, the No 1 drug maker, was close to a $68-billion purchase of United States rival Wyeth in a move to diversify its revenue base, sources...

Client Media Releases

NWU specialist receives innovation management award
Reduce packaging waste: Ipsos poll
What is transactional SMS?
MTN on data pricing